Experienced in Progressive Supranuclear Palsy Atypical

Dr. Meenakshi C. Patel

Geriatrics | Internal Medicine
6611 Clyo Rd, Suite E, 
Centerville, OH 
Accepting New Patients
Experienced in Progressive Supranuclear Palsy Atypical
6611 Clyo Rd, Suite E, 
Centerville, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Meenakshi Patel is a primary care provider, practicing in Geriatrics and Internal Medicine in Centerville, Ohio. Dr. Patel is rated as an Experienced provider by MediFind in the treatment of Progressive Supranuclear Palsy Atypical. Her top areas of expertise are Alzheimer's Disease, Hypertensive Heart Disease, Enlarged Liver, and Pediatric Myocarditis. Dr. Patel is currently accepting new patients.

Her clinical research consists of co-authoring 6 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Geriatrics
Internal Medicine
Licenses
Geriatric Medicine in OH
Hospital Affiliations
Miami Valley Hospital
Kettering Health Dayton
Languages Spoken
English
Hindi
Marathi
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Health
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

VALLEY MEDICAL PRIMARY CARE, INC
6611 Clyo Rd, Suite E, Centerville, OH 45459

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 29, 2025
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
A Phase 3, Randomized, Placebo-controlled, Observer-blind, Multi-country Study to Demonstrate the Efficacy of a Single Dose and Annual Revaccination Doses of GSK's RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Above
A Phase 3, Randomized, Placebo-controlled, Observer-blind, Multi-country Study to Demonstrate the Efficacy of a Single Dose and Annual Revaccination Doses of GSK's RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Above
Enrollment Status: Completed
Publish Date: July 31, 2025
Intervention Type: Biological
Study Drug: RSVPreF3
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
Enrollment Status: Completed
Publish Date: April 11, 2024
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab
Study Phase: Phase 2/Phase 3
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
Enrollment Status: Completed
Publish Date: July 01, 2022
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab, LY3853113 Anti-COVID-19 Antibody, VIR-7831 Anti-COVID-19 Antibody
Study Phase: Phase 2
Effect of LY3202626 on Alzheimer's Disease Progression as Measured by Cerebral ¹⁸F-AV-1451 Tau-PET in Mild Alzheimer's Disease Dementia
Effect of LY3202626 on Alzheimer's Disease Progression as Measured by Cerebral ¹⁸F-AV-1451 Tau-PET in Mild Alzheimer's Disease Dementia
Enrollment Status: Terminated
Publish Date: April 19, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Clinico-Pathological Study of the Correspondence Between 18F-AV-1451 PET Imaging and Post-Mortem Assessment of Tau Pathology
A Clinico-Pathological Study of the Correspondence Between 18F-AV-1451 PET Imaging and Post-Mortem Assessment of Tau Pathology
Enrollment Status: Completed
Publish Date: September 07, 2020
Intervention Type: Drug, Procedure
Study Phase: Phase 3
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Enrollment Status: Terminated
Publish Date: December 03, 2019
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
View 7 Less Clinical Trials

6 Total Publications

INSULIN GLARGINE 300 U/ML IS ASSOCIATED WITH LESS WEIGHT GAIN WHILE MAINTAINING GLYCEMIC CONTROL AND LOW RISK OF HYPOGLYCEMIA COMPARED WITH INSULIN GLARGINE 100 U/ML IN AN AGING POPULATION WITH TYPE 2 DIABETES.
INSULIN GLARGINE 300 U/ML IS ASSOCIATED WITH LESS WEIGHT GAIN WHILE MAINTAINING GLYCEMIC CONTROL AND LOW RISK OF HYPOGLYCEMIA COMPARED WITH INSULIN GLARGINE 100 U/ML IN AN AGING POPULATION WITH TYPE 2 DIABETES.
Journal: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
Published: November 07, 2017
Similar Doctors
Experienced in Progressive Supranuclear Palsy Atypical
Dr. Pawel M. Szczykutowicz
Geriatrics | Internal Medicine
Experienced in Progressive Supranuclear Palsy Atypical
Dr. Pawel M. Szczykutowicz
Geriatrics | Internal Medicine

Summit Medical Group Inc

1 Medical Village Dr, 
Edgewood, KY 
 (49.6 miles away)
859-212-4468
Languages Spoken:
English, Polish, Russian
See accepted insurances
Accepting New Patients

Pawel Szczykutowicz is a primary care provider, practicing in Geriatrics and Internal Medicine in Edgewood, Kentucky. Dr. Szczykutowicz is rated as an Advanced provider by MediFind in the treatment of Progressive Supranuclear Palsy Atypical. His top areas of expertise are Necrotizing Myopathy (NM), Anemia, Hospital-Acquired Pneumonia, and Atypical Pneumonia. Dr. Szczykutowicz is currently accepting new patients.

Experienced in Progressive Supranuclear Palsy Atypical
Dr. Syed A. Moqeeth
Geriatrics | Internal Medicine
Experienced in Progressive Supranuclear Palsy Atypical
Dr. Syed A. Moqeeth
Geriatrics | Internal Medicine
619 Oak St, Suite 645, 
Cincinnati, OH 
 (40.9 miles away)
513-569-6780
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Syed Moqeeth is a primary care provider, practicing in Geriatrics and Internal Medicine in Cincinnati, Ohio. Dr. Moqeeth is rated as a Distinguished provider by MediFind in the treatment of Progressive Supranuclear Palsy Atypical. His top areas of expertise are Thromboangiitis Obliterans, Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy, Vascular Dementia, and Dementia. Dr. Moqeeth is currently accepting new patients.

Experienced in Progressive Supranuclear Palsy Atypical
Dr. Olivia M. Rengering
Geriatrics | Internal Medicine
Experienced in Progressive Supranuclear Palsy Atypical
Dr. Olivia M. Rengering
Geriatrics | Internal Medicine

Oxford Physical Therapy And Rehabilitation

7567 Central Parke Blvd, A, 
Mason, OH 
 (24.2 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Olivia Rengering is a primary care provider, practicing in Geriatrics and Internal Medicine in Mason, Ohio. Dr. Rengering is rated as an Experienced provider by MediFind in the treatment of Progressive Supranuclear Palsy Atypical. Her top areas of expertise are Familial Combined Hyperlipidemia, Xanthoma, Cirrhosis, and High Cholesterol. Dr. Rengering is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Patel's expertise for a condition
ConditionClose
    View All 14 Advanced Conditions
    View All 93 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile